Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current. 

Category
done
done
done
Displaying 1 - 35 of 35
Date Sort descending
CL_2023-01.pdf

INFORMATION ONLY
Further Information on Expanded Use of Solvent Detergent Plasma: Updated Post Thaw Expiration, Sample Labels and Implementation Checklist

Customer Letter 2023-01 (PDF) | Recommended Solvent Detergent Plasma Hospital Implementation Checklist (PDF)Octaplasma: Blood Bank Communication (PDF) | Octaplasma B Label Mockup (PDF)Octaplasma A Label Mockup (PDF) | Octaplasma AB Label Mockup (PDF) | Octaplasma O Label Mockup (PDF)

CL_2023-02.pdf

INFORMATION ONLY
Update to Label Changes for Rare International Red Blood Cells

Customer Letter 2023-02 (PDF) | Attachment 1 (PDF)

CL_2023-03.pdf

ACTION REQUIRED
National Deployment of Pathogen-Reduced Platelets: Second Update

Customer Letter 2023-03 (PDF)

CL_2023-04.pdf

INFORMATION ONLY
Further Information on Expanded Use of Solvent Detergent Plasma: Education Materials and Ordering Information

Customer Letter 2023-04 (PDF) | Octaplasma® Customer Letter (PDF)Octaplasma® - Q&A for Transfusion Medicine Laboratory (PDF)

CL_2023-05.pdf

ACTION REQUIRED
Information on Immunoglobulin Inventory Following Results of the Request for Proposals (RFP) for Plasma-Derived Plasma Protein and Related Products (PPRP)

Customer Letter 2023-05 (PDF)

CL_2023-06.pdf

INFORMATION ONLY
Vonvendi® - Interim Plasma Protein and Related Products Review Decision

Customer Letter 2023-06 (PDF)

CL_2023-07.pdf

INFORMATION ONLY
NAC Recommendations for the Use of Solvent-Detergent Plasma in Canada; Important Changes to Post Thaw Storage of Octaplasma

Customer Letter 2023-07 (PDF) | Octaplasma® Advisory Letter (PDF)

CL_2023-08.pdf

INFORMATION ONLY
Alprolix and Eloctate Packaging Changes

Customer Letter 2023-08 (PDF) | ALPROLIX Hemophilia B Enrolment Form (PDF) | ELOCTATE Hemophilia A Enrolment Form (PDF) | ALPROLIX - ELOCTATE Notification Letter (PDF)

CL_2023-09.pdf

ACTION REQUIRED
National Deployment of Pathogen-Reduced Platelets: Third Update

Customer Letter 2023-09 (PDF)

CL_2023-10.pdf

ACTION REQUIRED
Shelf Life Extension of Pooled Platelets Psoralen-Treated Components from 5 to 7 Days

Customer Letter 2023-10 (PDF)

CL_2023-11.pdf

INFORMATION ONLY
FAQ for the Request for Proposals (RFP) for Immunoglobulins and other Plasma Protein and Related Products (PPRP)

Customer Letter 2023-11 (PDF) | 2023 IVIg Transition FAQ (PDF)

CL_2023-12.pdf

ACTION REQUIRED
National Deployment of Pathogen-Reduced Platelets: Fourth Update

Customer Letter 2023-12 (PDF)

CL_2023-13.pdf

ACTION REQUIRED
Health Canada Approved - Apheresis Platelets Psoralen-treated and Apheresis Platelets PAS-E Added

Customer Letter 2023-13 (PDF)

CL_2023-14.pdf

INFORMATION ONLY
Cytogam Shortage – Temporary Supply of US-labelled Cytogam

Customer Letter 2023-14 (PDF) | Important Information on Cytogam Shortage - Temporary Supply of US-labelled Cytogam (PDF)

CL_2023-15.pdf

INFORMATION ONLY
Panzyga, Octagam and Cutaquig Unavailable for Exceptional Access Cases

Customer Letter 2023-15 (PDF)

CL_2023-16.pdf

INFORMATION ONLY
New Manual Contingency Process for Release Labelling

Customer Letter 2023-16 (PDF)

CL_2023-17.pdf

ACTION REQUIRED
National Deployment of Pathogen-Reduced Platelets: Fifth Update 

Customer Letter 2023-17 (PDF)

CL_2023-18.pdf

INFORMATION ONLY
Revision of Request for RHD Genotyping Form

Customer Letter 2023-18 (PDF)

CL_2023-19.pdf

INFORMATION ONLY
Fibryga – Notice of Shelf-Life Extension to 48 Months

Customer Letter 2023-19 (PDF) | Fibryga® Shelf-Life Extension (PDF)

CL_2023-20.pdf

INFORMATION ONLY
Update On Expanded Use of Solvent Detergent Plasma

Customer Letter 2023-20 (PDF)

CL_2023-21.pdf

INFORMATION ONLY
Substituting Frozen Plasma

Customer Letter 2023-21 (PDF)

CL_2023-22.pdf

INFORMATION ONLY
Changes to Rad-Sure Irradiation Indicator Labels

Customer Letter 2023-22 (PDF)

CL_2023-23.pdf

INFORMATION ONLY
Update to Special Request Order Form

Customer Letter 2023-23 (PDF)

CL_2023-24.pdf

ACTION REQUIRED
FEIBA Defect – Particles in BAXJECT II HF Device

Customer Letter 2023-24 (PDF) | Takeda Customer Letter (PDF)

CL_2023-25.pdf

INFORMATION ONLY
Fibryga – Notice of Shelf-Life Extension to 48 Months (Revision)

Customer Letter 2023-25 (PDF) | Fibryga® Shelf-Life Extension – Revised Letter (PDF)

CL_2023-26.pdf

INFORMATION ONLY
Additional Information for Thawing Octaplasma

Customer Letter 2023-26 (PDF) | Thawing of Octaplasma Additional Information (PDF)

CL_2023-27.pdf

INFORMATION ONLY
Introduction of HyQvia

Customer Letter 2023-27 (PDF) | Introducing HyQviaMD in Canada (PDF)

CL_2023-28.pdf

ACTION REQUIRED
Update on Panzyga, Cutaquig and Octagam Availability

Customer Letter 2023-28 (PDF)

CL_2023-29.pdf

INFORMATION ONLY
New Tamper Indication Device Trial

Customer Letter 2023-29 (PDF)

CL_2023-30.pdf

INFORMATION ONLY
Health Canada Letter on Mixing of Red Blood Cells with Solvent Detergent Plasma

Customer Letter 2023-30 (PDF) | Health Canada letter (PDF)

CL_2023-31.pdf

INFORMATION ONLY
Introduction of Glassia

Customer Letter 2023-31 (PDF)

CL_2023-32.pdf

INFORMATION ONLY
Packaging Change for WinRho 1500IU

Customer Letter 2023-32 (PDF) | WinRho Product Monograph (PDF) | WinRho Customer Letter (PDF)

CL_2023-33.pdf

INFORMATION ONLY
Manufacturing Changes for Cytogam

Customer Letter 2023-33 (PDF) | Cytogam Product Monograph (PDF) | Cytogam Customer Letter (PDF)

CL_2023-34.pdf

INFORMATION ONLY
Notice of Upcoming Network Outages Affecting Hospital Portal

Customer Letter 2023-34 (PDF)

CL_2023-35.pdf

INFORMATION ONLY
2023 Holiday Message and Inventory Update

Customer Letter 2023-35 (PDF)